Comparison of the clinical effectiveness of zanamivir and laninamivir octanoate for children with influenza A(H3N2) and B in the 2011–2012 season
Version of Record online: 19 AUG 2013
© 2013 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Influenza and Other Respiratory Viruses
Volume 8, Issue 2, pages 151–158, March 2014
How to Cite
2013) Comparison of the clinical effectiveness of zanamivir and laninamivir octanoate for children with influenza A (H3N2) and B in the 2011–2012 season. Influenza and Other Respiratory Viruses 8(2), 151–158.et al. (
- Issue online: 26 FEB 2014
- Version of Record online: 19 AUG 2013
- Manuscript Accepted: 30 JUN 2013
- Grant-in-Aid for Scientific Research (C). Grant Number: 22591174
- Ministry of Education, Science, Sports and Culture of Japan
- Global COE Program
- GlaxoSmithKline, Inc.
- Meiji Seika Pharma Co., Ltd
- 10Clinical effectiveness of neuraminidase inhibitors–oseltamivir, zanamivir, laninamivir, and peramivir–for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010–2011 influenza season in Japan. J Infect Chemother 2012; 18:858–864., , et al.
- 12WHO information for molecular diagnosis of influenza virus in humans – update. Available at http://www.who.int/influenza/resources/documents/molecular_diagnosis_influenza_virus_humans_update_201108.pdf (Accessed 6 August 2012).